Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jul;12(7):1039-50.
doi: 10.2217/pgs.11.48.

Pharmacogenomics of cisplatin-induced ototoxicity

Debashree Mukherjea  1 , Leonard P Rybak
Affiliations
Review

Pharmacogenomics of cisplatin-induced ototoxicity

Debashree Mukherjea et al. Pharmacogenomics. 2011 Jul.

Abstract

Cisplatin ototoxicity affects different individuals in a widely variable manner. These variations are likely to be explained by genetic differences among those affected. It would be highly advantageous to identify genetic variants that predispose to cisplatin ototoxicity in order to minimize the risk to susceptible subgroups. Although this area of research is very important, only a few studies have rigorously examined the genetic basis for cisplatin-induced susceptibility to hearing loss. This article addresses recent progress in clarifying the incidence of cisplatin ototoxicity and the risk factors and controversies regarding the identification of genetic variants associated with cisplatin-induced hearing loss.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

Bibliography

    1. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf. 1995;13:228–244. - PubMed
    1. Chen WC, Jackson A, Budnick AS, et al. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer. 2006;106:820–829. - PubMed
    1. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur. J. Cancer. 2004;40:2445–2451. - PubMed
    1. Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J. Pediatr. Hematol. Oncol. 2007;29:355–360. - PubMed
    1. Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer. 2006;107:417–422. - PubMed

Websites

    1. Drug metabolism. www.drugmetabolism.co.uk/gst.aspx.
    1. The Pharmacogenomics Knowledge Base. www.pharmgkb.org.
    1. Protein knowledgebase. www.uniprot.org.
    1. The Signaling Gateway. www.signaling-gateway.org.
    1. International HapMap Consortium. www.ncbi.nlm.nih.gov/pubmed/16255080.

Publication types

MeSH terms